Nadia Harbeck, MD, PhD, LMU Munich, Munich, Germany, talks on upcoming novel therapies for use in HER2-positive (HER2+) metastatic breast cancer. Tucatinib, a highly selective tyrosine kinase inhibitor targeting HER2, has recently been approved in Europe for patients with locally advanced or metastatic HER2+ breast cancer, based on data from the HER2CLIMB study (NCT02614794). Trastuzumab deruxtecan (T-DXd), a novel antibody-drug conjugate, has also been granted conditional approval in Europe in this setting. Studies investigating T-DXd are ongoing and further results are enthusiastically awaited. This interview took place during the 17th St. Gallen International Breast Cancer Conference.